Different regions have distinct healthcare systems, varying access levels, reimbursement models, and treatment realities — ...

Uniting leaders pioneering complement-targeted therapies across ophthalmology, neurodegeneration, nephrology, oncology and ...

At present, the only FDA-approved oral therapies for HAE are BioCryst's Orladeyo (berotralstat) and KalVista Pharma's Ekterly ...

It's well-established that breathing exercises can improve symptoms in COPD by freeing stale air that remains trapped in the ...

Omnideployment is not about multiplying touchpoints or increasing the volume of communications. It is the precise ...

Speaking to investors and analysts at its capital markets day in London, UK, Sandoz presented its new strategy – Bio100 – ...

Hard on the heels of a big disappointment in its cardiovascular pipeline, Novartis has suffered another – this time for its ...

As cell therapy for autoimmune disease transitions from breakthrough clinical case studies to broad clinical validation, developers are racing to overcome challenges around safety, scalability, ...

While much of this can be attributed to lack of efficacy, factors such as poor clinical trial design and challenges with ...

That's the conclusion of the latest Association of the British Pharmaceutical Industry (ABPI) competitiveness report (PDF), ...

An NHS trust in the UK has become the first site in Europe to offer Roche's experimental drug trontinemab to patients ...

Novo Nordisk has opted to discontinue two late-stage trials of IL-6 inhibitor ziltivekimab in heart failure, after an interim ...